Drug Profile
Empasiprubart - argenx/Broteio Pharma
Alternative Names: ARGX-117Latest Information Update: 15 Apr 2024
Price :
$50
*
At a glance
- Originator argenx; Broteio Pharma
- Developer argenx
- Class Antianaemics; Antibodies; Antivirals
- Mechanism of Action Complement system protein inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Delayed graft function; Dermatomyositis; Multifocal motor neuropathy
- Phase I Kidney disorders
- No development reported Motor neuron disease
- Discontinued COVID 2019 infections
Most Recent Events
- 15 Apr 2024 Phase-II clinical trials in Dermatomyositis (IV) (Argenx pipeline, April 2024)
- 17 Feb 2024 Phase-II clinical trials in Delayed graft function in Australia, Canada, Belgium, Portugal, Spain (IV) (NCT05907096) (EudraCT2022-503091-89-00)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Motor-neuron-disease(In volunteers) in Netherlands (SC)